Specifically, a Phase 1/1b first-in-human dose escalation/dose expansion study (NCT03927261) is evaluating the safety of PRGN-3006 UltraCAR T co-expressing an anti-CD33 CAR and mbIL15 in adult patients with r/r AML, hypomethylating agents (HMA) failure, high risk MDS and chronic myelomonocytic leukemia (CMML). Here, CD33 is linked to myelodysplastic syndrome.